AD Vaccines: Conclusions and Future Directions
Open accessAbstract
Full text available
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There have been hints of some beneficial effects (clinical and biochemical) linked to human anti-Aβ immunotherapies.
“In fact, there have been hints of some beneficial effects (clinical and biochemical) linked to human anti-Aβ immunotherapies (74-79).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 59 · Cited by 14
Research works printed but not linked: 1
- [39]Asuni A Boutajangout A Scholtzova H Knudsen E Li Y Quartermain D Frangione B Wisniewski T Sigurdsson EM Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer’s model mice Ear. J. Neurosci 2006 24 2530 42 PMC1779823 17100841
- Authors
- Wisniewski, T.
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-04-01
- Volume
- 8
- Issue
- 2
- Pages
- 160-166
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- PMC
- PMC3124076
- OpenAlex
- W2065082424
- Cited by
- 14
- References
- 59
- Citations by year
- 2026: 2 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2013: 1 · 2012: 1
- FWCI
- 0.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- CNS & Neurological Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG015408, R01AG020245)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adjuvants, vaccine adjuvants, adjuvant vaccine, immunogenicity, adjuvant safety
- MeSH terms
- Alzheimer Disease, Animals, Clinical Trials as Topic, Disease Models, Animal, Humans, Drug Design, Amyloid beta-Peptides, Immunotherapy, Active, Cerebral Amyloid Angiopathy, Neurofibrillary Tangles, Alzheimer Vaccines, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
